#Health / Well-being #Therapeutics
- Ophthalmology
- Technologies
- Cationorm®
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Health / Well-being #Therapeutics
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Santen Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.
BACKGROUND
For 120 years now, Santen has been continuing its commitment to improving the eyesight and health of patients across the globe, building upon a spirit of creation, innovation and strong company values.
Santen SAS has been marketing the company’s ophthalmological products in France since 2014. The French company is also a Santen Group Center of Excellence dedicated to innovative ophthalmological R&D for all eye segments.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Santen SAS has a sales and marketing organization to commercialize pharmaceutical ophthalmic products in France.
In terms of research activities, within Santen we have concentrated our basic research, non-clinical studies, and drug formulation research at Nara R&D Center, so as to integrate the knowledge of our various sections and create better products. In 2011, Santen purchased Novagali Pharma (today Santen S.A.S.), a French ophthalmic pharmaceutical company that has excellent R&D capability and drug formulation technologies in the dry eye field. This purchase has reinforced Santen’s development pipelines, enhancing its international competitiveness in the ophthalmic field.
28 patents
78 staff members (in France)
Strengths:
Cationorm®, the first cationic emulsion to treat dry eye symptoms, marketed in more than 50 countries. A portfolio comprising a range of products at various stages of development, particularly the marketed medications Ikervis®, indicated for the treatment of severe keratitis in patients presenting dry eye symptoms, and Verkazia® indicated in severe vernal keratoconjunctivitis in children and adolescents.
Innovation assets:
Development of innovative ophthalmological products, patented technologies, bioavailability, tolerability
In same field